Research
Lactobacillus fermentum
26 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 improved liver function and uric acid management-A pilot study.
A placebo-controlled, double-blinded, randomized clinical trial with 82 participants explored the effects of probiotics Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05 on liver function and uric acid levels. The study found significant reductions in serum AST, ALT, and UA levels, and improvements in gut microbiota composition, suggesting potential benefits for asymptomatic MAFLD.
Breast microecology improvement using probiotics following needle aspiration in patients with lactational breast abscess: a multi-center randomized double-blind controlled trial.
This multi-center randomized double-blind controlled trial investigated the effect of Lactobacillus fermentum CECT5716 on breast microecology and inflammatory response in patients with lactational breast abscesses. The experimental group showed a significantly higher 5-day cure rate compared to the control group, indicating that L. fermentum can shorten healing time in these patients.
Oral Lactobacillus fermentum CECT5716 in the patients with lactational abscess treated by needle aspiration: The late follow-up of a randomized controlled trial.
RCT of 101 lactating women with breast abscess comparing oral Lactobacillus fermentum CECT5716 to maltodextrin after needle aspiration. The probiotic group had a significantly lower rate of stopping breastfeeding due to recurrence of mastitis compared to the control group.
Evaluation of the safety, tolerance and efficacy of 1-year consumption of infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40 or Bifidobacterium breve CECT7263: a randomized controlled trial.
RCT evaluating the safety, tolerance, and effects of infant formula supplemented with L. fermentum CECT5716 or B. breve CECT7263 in 236 infants over one year. No significant differences in weight gain were observed. B. breve reduced crying risk, and L. fermentum reduced diarrhea incidence and duration.
Study protocol: evaluation of the probiotic Lactobacillus Fermentum CECT5716 for the prevention of mastitis in breastfeeding women: a randomised controlled trial.
This study protocol outlines a double-blind randomized controlled trial to evaluate the effectiveness of the probiotic Lactobacillus Fermentum CECT5716 in preventing mastitis in breastfeeding women. A total of 600 women will be randomized to receive either the probiotic or a placebo for 8 weeks postpartum, with primary and secondary outcomes including mastitis incidence, breastfeeding duration, and maternal and infant health.
Children with atopic dermatitis show clinical improvement after Lactobacillus exposure.
A double-blind, randomized placebo-controlled trial on 220 children with moderate-to-severe atopic dermatitis assessed the effects of Lactobacillus paracasei, Lactobacillus fermentum, and their mixture. The probiotic groups showed lower SCORAD, FDLQI, and CDLQI scores compared to placebo, indicating clinical improvement in atopic dermatitis.
Effects of probiotic-supplemented diets on growth performance and intestinal immune characteristics of broiler chickens.
This study investigated the effects of a probiotic product containing Lactobacillus fermentum and Saccharomyces cerevisiae on growth performance and intestinal immune status in broiler chickens. Probiotic-supplemented diets improved ADG and feed efficiency and increased T-cell immune markers without decreasing growth performance during 1 to 21 days.
Reduced lesions in chickens with Clostridium perfringens-induced necrotic enteritis by Lactobacillus fermentum 1.20291.
RCT examining the effects of Lactobacillus fermentum 1.2029 on necrotic enteritis in chickens. The probiotic reduced the severity of lesions and inflammation, regulated the intestinal mucosal immune response, and altered cytokine and TLR expression levels.
Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk.
RCT comparing the efficacy of oral administration of Lactobacillus fermentum CECT5716 or Lactobacillus salivarius CECT5713 to antibiotic therapy in 352 women with infectious mastitis. The probiotic groups showed lower bacterial counts and improved outcomes compared to the antibiotic group, suggesting probiotics as an efficient alternative treatment.
A canine-specific probiotic product in treating acute or intermittent diarrhea in dogs: A double-blind placebo-controlled efficacy study.
A double-blind placebo-controlled study on 60 dogs with acute diarrhea tested a sour-milk product containing Lactobacillus fermentum, L. rhamnosus, and L. plantarum. The probiotic treatment normalized stool consistency, enhanced well-being, and reduced concentrations of Clostridium perfringens and Enterococcus faecium in feces compared to placebo.
Lactobacillus fermentum CECT 5716 Reduces Staphylococcus Load in the Breastmilk of Lactating Mothers Suffering Breast Pain: A Randomized Controlled Trial.
RCT evaluating three doses of Lactobacillus fermentum CECT5716 to reduce Staphylococcus load in breastmilk of women with painful breastfeeding. Significant decrease in Staphylococcus load and breast pain was observed in probiotic groups compared to control.
Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: A clinical study.
Clinical trial assessing the effectiveness of Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in slow-release vaginal tablets for preventing recurrent vulvovaginal candidiasis in 58 women. 72.4% of participants experienced no clinical recurrence over a 7-month observation phase.
Effect of intranasal administration of Lactobacillus fermentum CJL-112 on horizontal transmission of influenza virus in chickens.
The study investigated the effect of intranasal administration of Lactobacillus fermentum CJL-112 on preventing horizontal transmission of H9N2 avian influenza virus in chickens. The administration significantly decreased viral shedding from the gastrointestinal and respiratory tracts, suggesting it may be an effective alternative to control H9N2 AIV infection.
Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants.
A randomized double-blinded controlled study examined the effects of a follow-on formula containing Lactobacillus fermentum CECT5716 on infection incidence in infants aged 6 to 12 months. The experimental group showed significant reductions in gastrointestinal and upper respiratory tract infections compared to the control group.
Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes.
RCT of 99 competitive cyclists evaluating the effects of Lactobacillus fermentum supplementation on gastrointestinal and respiratory illness symptoms. Probiotic increased Lactobacillus numbers and reduced severity of gastrointestinal illness in males, but effects on URTI and symptoms in females were uncertain.
Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1-6 months of age: a randomized controlled trial.
RCT evaluating the safety and tolerance of an infant formula supplemented with Lactobacillus fermentum CECT5716 in infants aged 1-6 months. No significant differences in weight gain or formula tolerance were observed, but the probiotic group had a lower incidence of gastrointestinal infections.
Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination.
A randomized, double-blinded, placebo-controlled trial with 50 volunteers studied the coadjuvant capability of oral Lactobacillus fermentum CECT5716 for an anti-influenza vaccine. The probiotic group showed increased natural killer cells, T-helper type 1 cytokine concentrations, and antigen-specific immunoglobulin A, with a lower incidence of influenza-like illness compared to the placebo group.
Effects of probiotics on atopic dermatitis: a randomised controlled trial.
RCT of 56 children with moderate or severe atopic dermatitis comparing probiotic Lactobacillus fermentum VRI-033 PCC to placebo over 8 weeks. The probiotic group showed significant improvement in the Severity Scoring of Atopic Dermatitis (SCORAD) index compared to placebo.
A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules.
Double-blind placebo-controlled study of adjuvant lactobacilli treatment after vaginal clindamycin ovules in women with bacterial vaginosis. The study found no improvement in cure rates with lactobacilli-prepared tampons compared to placebo.
Effectiveness of the two microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, formulated in slow-release vaginal tablets, in women affected by bacterial vaginosis: a pilot study.
Pilot RCT assessing the effectiveness of Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01 in slow-release vaginal tablets for women with bacterial vaginosis. The study found significant reduction in Nugent scores, indicating improved vaginal microbiota in the active group compared to placebo.
Synbiotic administration of canine-derived strain Lactobacillus fermentum CCM 7421 and inulin to healthy dogs.
RCT in healthy adult dogs testing the effects of Lactobacillus fermentum CCM 7421 and inulin on faecal microbial populations, faecal characteristics, and blood biochemistry. The synbiotic combination did not enhance probiotic efficacy but showed a slight laxative effect, potentially useful for preventing constipation.
Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes.
A double-blind, placebo-controlled, crossover trial evaluated the probiotic Lactobacillus fermentum VRI-003 (PCC) in 20 elite male distance runners over 4 months. PCC treatment significantly reduced the number of days with respiratory symptoms and illness severity compared to placebo, with no significant changes in running performance.
Growth-promoting effects of single-dose intragastrically administered probiotics in chickens.
RCT measuring live body weight gain and food conversion efficiency in Kabir strain chicks inoculated with Lactobacillus fermentum or Lactobacillus spp. (Autruche 4). Both treatments improved weight gain and food conversion efficiency compared to controls, with Lactobacillus fermentum showing superior results.
Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol.
RCT assessing the effects of Lactobacillus fermentum on LDL cholesterol and other lipid fractions in subjects with elevated cholesterol. The study found a modest downward trend in LDL cholesterol for both Lactobacillus fermentum and placebo, but the changes were not statistically significant.
Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD.
Double-blind cross-over RCT with 14 patients investigating the effect of Lactobacillus fermentum KLD on small intestinal bacterial overgrowth. The study found no significant difference between Lactobacillus treatment and placebo in hydrogen breath test results, stool frequency, or symptom scores.
Human oral isolate Lactobacillus fermentum AGR1487 reduces intestinal barrier integrity by increasing the turnover of microtubules in Caco-2 cells.
In vitro study of Lactobacillus fermentum AGR1487 on Caco-2 cells, showing it reduces intestinal barrier integrity by increasing microtubule turnover. AGR1487 increased expression of tubulin genes and microtubule-associated proteins, affecting tight junctions.